» Articles » PMID: 36697763

A Truncated and Catalytically Inactive Isoform of KDM5B Histone Demethylase Accumulates in Breast Cancer Cells and Regulates H3K4 Tri-methylation and Gene Expression

Overview
Date 2023 Jan 25
PMID 36697763
Authors
Affiliations
Soon will be listed here.
Abstract

KDM5B histone demethylase is overexpressed in many cancers and plays an ambivalent role in oncogenesis, depending on the specific context. This ambivalence could be explained by the expression of KDM5B protein isoforms with diverse functional roles, which could be present at different levels in various cancer cell lines. We show here that one of these isoforms, namely KDM5B-NTT, accumulates in breast cancer cell lines due to remarkable protein stability relative to the canonical PLU-1 isoform, which shows a much faster turnover. This isoform is the truncated and catalytically inactive product of an mRNA with a transcription start site downstream of the PLU-1 isoform, and the consequent usage of an alternative ATG for translation initiation. It also differs from the PLU-1 transcript in the inclusion of an additional exon (exon-6), previously attributed to other putative isoforms. Overexpression of this isoform in MCF7 cells leads to an increase in bulk H3K4 methylation and induces derepression of a gene cluster, including the tumor suppressor Cav1 and several genes involved in the interferon-alpha and -gamma response. We discuss the relevance of this finding considering the hypothesis that KDM5B may possess regulatory roles independent of its catalytic activity.

Citing Articles

To Erase or Not to Erase: Non-Canonical Catalytic Functions and Non-Catalytic Functions of Members of Histone Lysine Demethylase Families.

Di Nisio E, Manzini V, Licursi V, Negri R Int J Mol Sci. 2024; 25(13).

PMID: 39000010 PMC: 11241480. DOI: 10.3390/ijms25136900.


KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges.

Li C, Wang W, Leung C, Yang G, Chen J Mol Cancer. 2024; 23(1):109.

PMID: 38769556 PMC: 11103982. DOI: 10.1186/s12943-024-02011-0.


The emerging roles of histone demethylases in cancers.

Tong D, Tang Y, Zhong P Cancer Metastasis Rev. 2024; 43(2):795-821.

PMID: 38227150 DOI: 10.1007/s10555-023-10160-9.


Entecavir: A Review and Considerations for Its Application in Oncology.

Lourenco T, Vale N Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004468 PMC: 10675314. DOI: 10.3390/ph16111603.


Knockdown of KDM5B Leads to DNA Damage and Cell Cycle Arrest in Granulosa Cells via MTF1.

Yang Y, Cai Y, Guo J, Dai K, Liu L, Chen Z Curr Issues Mol Biol. 2023; 45(4):3219-3237.

PMID: 37185734 PMC: 10136914. DOI: 10.3390/cimb45040210.

References
1.
Jamshidi S, Catchpole S, Chen J, So C, Burchell J, Rahman K . KDM5B protein expressed in viable and fertile ΔARID mice exhibit no demethylase activity. Int J Oncol. 2021; 59(5). PMC: 8562390. DOI: 10.3892/ijo.2021.5276. View

2.
Lu P, Sundquist K, Baeckstrom D, Poulsom R, Hanby A, Jones T . A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J Biol Chem. 1999; 274(22):15633-45. DOI: 10.1074/jbc.274.22.15633. View

3.
Li Q, Shi L, Gui B, Yu W, Wang J, Zhang D . Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res. 2011; 71(21):6899-908. DOI: 10.1158/0008-5472.CAN-11-1523. View

4.
Bueno M, Richard S . SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase. Epigenetics. 2013; 8(11):1162-75. DOI: 10.4161/epi.26112. View

5.
Jorgovanovic D, Song M, Wang L, Zhang Y . Roles of IFN-γ in tumor progression and regression: a review. Biomark Res. 2020; 8:49. PMC: 7526126. DOI: 10.1186/s40364-020-00228-x. View